ENETS Task Forces & Working Groups

In 2021, ENETS streamlined its various scientific activities into two categories: task forces and working groups. Task forces are established groups whose aim is to answer scientific questions. Standing working groups, on the other hand, have been established to address topics such as ENETS education, ENETS database, and the ENETS Centers of Excellence (CoE) programme.

ENETS Task Forces

The aim of a task force is to address challenging clinical and scientific issues and promote ENETS research. The group structure is variable but should consist of Advisory Board members, leading experts in the field outside of the Advisory Board as well as representatives of different countries. The groups are multi-disciplinary.

Ongoing task forces comprise:

  • Theragnostics in NEN
  • High grade NEN G3
  • Clinical trials
  • Lung NET
  • MEN-1
  • Carcinoid Heart Disease (CHD).

CHD task force leaflet

The ENETS CHD task force has compiled a leaflet for patients suffering from CHD. To find out more about this disease, click on the link below.

ENETS Working Groups

ENETS Database

ENETS has a long experience in rare tumors and has a high level of expertise and multi-center cooperation resulting from its networking with ENETS certified centers of (ENETS Centers of Excellence - CoE) in Europe as well as non-European countries, such as the USA, Australia, and others. ENETS has hosted a registry for neuroendocrine tumors since 2008.

ENETS Education

This newly-established working group focuses on ENETS’ continuous education programme in 2021 and beyond. The aim of this group is to restructure and streamline all ENETS educational activities, including physical and virtual learning activities. The group set up the ENETS webinar series in 2021, which has been accredited by the UEMS.

ENETS/UEMS NEN Specialist Curriculum

ENETS has been working closely with the UEMS to establish the European Training Requirements (ETR) for the MJC/RUD NEN (for trainees, trainers, and training centers). The ETR was approved by the UEMS Council in July 2020. Subsequently, the UEMS also approved to set up a multidisciplinary joint committee (MJC) for neuroendocrine neoplasia medicine.